Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

  • Technology appraisal guidance
  • TA285
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence